Detalhe da pesquisa
1.
Predictors for multiple sclerosis relapses after switching from natalizumab to fingolimod.
Mult Scler
; 20(13): 1714-20, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-24842961
2.
Intravenous immunoglobulin maintenance treatment in myasthenia gravis: a randomized, controlled trial sample size simulation.
Muscle Nerve
; 50(6): 999-1004, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24710856
3.
Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients.
Mult Scler
; 19(11): 1454-61, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23439578
4.
Preference-based Health status in a German outpatient cohort with multiple sclerosis.
Health Qual Life Outcomes
; 11: 162, 2013 Oct 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-24089999
5.
Sibling disability risk at onset and during disease progression in familial multiple sclerosis.
Mult Scler
; 17(9): 1060-6, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21561958
6.
Alternative splicing of the TNFSF13B (BAFF) pre-mRNA and expression of the BAFFX1 isoform in human immune cells.
Gene
; 760: 145021, 2020 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32763489
7.
Acetylcholine Receptor Antibody Titers and Clinical Course after Influenza Vaccination in Patients with Myasthenia Gravis: A Double-Blind Randomized Controlled Trial (ProPATIent-Trial).
EBioMedicine
; 28: 143-150, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29337134
8.
Myasthenia gravis: analysis of serum autoantibody reactivities to 1827 potential human autoantigens by protein macroarrays.
PLoS One
; 8(3): e58095, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23483977
9.
Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis.
J Neurol
; 260(5): 1382-7, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23266894